Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accounts Payables (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Accounts Payables for 10 consecutive years, with $31.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 20.51% to $31.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.0 million through Dec 2025, down 20.51% year-over-year, with the annual reading at $31.0 million for FY2025, 20.51% down from the prior year.
  • Accounts Payables for Q4 2025 was $31.0 million at Ultragenyx Pharmaceutical, down from $40.6 million in the prior quarter.
  • The five-year high for Accounts Payables was $59.8 million in Q2 2024, with the low at $15.6 million in Q3 2021.
  • Average Accounts Payables over 5 years is $35.0 million, with a median of $35.1 million recorded in 2024.
  • The sharpest move saw Accounts Payables soared 152.5% in 2022, then plummeted 42.75% in 2025.
  • Over 5 years, Accounts Payables stood at $17.1 million in 2021, then surged by 152.5% to $43.3 million in 2022, then decreased by 2.68% to $42.1 million in 2023, then decreased by 7.39% to $39.0 million in 2024, then decreased by 20.51% to $31.0 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $31.0 million, $40.6 million, and $34.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.